<DOC>
	<DOCNO>NCT00261976</DOCNO>
	<brief_summary>This study evaluate long-term safety infliximab ( Remicade )</brief_summary>
	<brief_title>A Long-term Safety Study Infliximab ( Remicade )</brief_title>
	<detailed_description>The purpose study collect long-term safety information infliximab ( Remicade ) patient participate research study use drug . All patient study ask participate long-term safety follow-up study provide important information study drug . The long-term effect study drug survival , serious infection , new malignancy new autoimmune disease measure data collect 5-year period . Additional information possible delay allergic reaction ( possible fever , rash , fatigue , joint pain ) also collect receive infliximab ( Remicade ) end primary study . Study participation research study 5 year end primary study . Questionnaires complete patient 's health occurrence safety event interval 6 month , 1 year , 2 year , 3 year , 4 year 5 year patient complete participation primary study .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>All patient enrol ongoing future Centocor sponsor infliximab clinical study require longterm safety followup ( ie , primary study ) . Patients must receive least 1 dose study agent eligible participation study Did previously participate Centocor sponsor infliximab clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>Crohn 's disease</keyword>
	<keyword>Psoriasis</keyword>
</DOC>